Biotech | March 16, 2022
Sanofi announces €300 million collaboration with Blackstone Life Sciences
The investment will accelerate the overall Sarclisa development program
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
100% efficacy against severe Covid-19 disease and hospitalizations
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Subscribe To Our Newsletter & Stay Updated
